March 21, 2025 8:04am

The simultaneous expiration of stock options, index futures, and index futures options, occurs 4 times a year

News: Alnylam Pharmaceuticals (ALNY +$12.71 or +5.01% to $253.54) the FDA approval of the supplemental New Drug Application (sNDA) for its RNAi therapeutic, AMVUTTRA® (vutrisiran), for the treatment of the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis (ATTR-CM) in adults to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failure visits. The approval expands the indication for AMVUTTRA.

  • ATTR-CM is a devastating, rapidly progressive, and ultimately fatal disease estimated to affect approximately 150,000 people in the U.S. and over 300,000 people worldwide. There is no cure for ATTR-CM, and the deposition of misfolded transthyretin (TTR) fibrils causes irreversible damage over time which can lead to premature death. Today, most patients remain undiagnosed and untreated, and a significant portion of those who are treated with commonly used therapies experience disease progression.

Pre-open Indications: 3 Positive and 3 Negative Indications

No false narratives or fake news; to read insights and analysis on the latest sector action, check out Pre-Open Brief …

Never leave an investor uninform

Remember that overnight and pre-open actions’ futures and markets doesn’t necessarily translate into actual trading in today’s market session.

My interpretation of the morning’s numbers is written to be informative; it’s built on what happened to make “it” happen today!

 

Thursday’s night’s … RegMed Investors (RMi) Closing Bell: a short-term window… https://www.regmedinvestors.com/articles/13848

 

Friday: The pre-open Dow futures are DOWN -0.33% or (-141 points), the S&P futures are DOWN -0.28% or (-16 points) and the Nasdaq futures are DOWN -0.40% or (-78 points)

  • U.S. stock futures are falling Friday morning, 3/21
  • European markets were lower,
  • Asia Pacific markets were mixed.

 

Henry’omics: We need to more than consider the economic environment to comprehend the micro re “our” universe of cell and gene therapy companies

Thursday’s action follows a losing session for the S&P 500 slipped- 0.2%, while the Nasdaq dropped- 0.3% as the Dow lost -0.03%.

For the week, the Dow is on track for a 1.1% gain, marking its best weekly performance since late January, the Nasdaq is off -0.4%, heading for its 5th straight losing week and its longest stretch of weekly losses since May 2022 while the S&P 500 is on pace for a +0.4% advance.

Economic Data Docket: St. Louis Fed Economic News Index, ICE BofA Indices, Unemployment Insurance Weekly Claims Report and Interest Rate on Reserve Balances

 

Q1/25:  March sessions with 7 positive and 8 negative closes

  • February – 1 holiday, 11 negative and 8 positive closes
  • January – 2 holidays, 1 market close, 10 negative and 10 positive closes

Q4/24:

  • December 1 holiday, 15 negative and 5 positive closes
  • November 10 negative and 9 positive closes
  • October: 8 positive and 15 negative closes

 

Companies in my headlights – It’s your decision; I provide ideas and context

I post about “indication intelligence” looking toward investment conferences … to assist investors with insight into sector vulnerabilities and strengths.

A dictionary definition of “indicate” refers to something less than a certainty; an indication could be a signal of being oversold or overbought, a recommendation, or grounds for inferring or a basis for believing.

Better part of valor to not lead any investor to temptation; yet again, I am passing on forecasting the daily indications as to expectation while the aftermarket blanked while the pre-open waits for the …  econs, it is still a mix of ups, downs and just uncertainty.

However, pre-open:

Positive Indications:

  • Alnylam Pharmaceuticals (ALNY) closed up +$0.10 with a positive +$12.71 or +5.01%
  • Ultragenyx Pharmaceuticals (RARE) closed down -$0.79 with a positive +$0.70 or +1.80%
  • Vericel (VCEL) closed down -$0.25 with a positive +$0.32 or +0.68%

Negative Indications:

  • Beam Therapeutics (BEAM) closed down -0.77 with a negative -$0.08 or -0.35%
  • CRISPR Therapeutics (CRSP) closed down -$0.77 with a negative -$0.17 or +1.80%
  • Lenz Therapeutics (LENZ) closed up =$0.78 with a negative -0.24 or -0.91%

 

The BOTTOM LINE: Another week, the 3rd of March, Tuesday closed negative after Monday’s positive closes

  • As I have written, “uncle algo and his trading dwarfs” will determine the heights or lows of share pricing”

March to date:

  • 3/20 – Thursday closed negative with 10 positive, 23 negative and 2 flats
  • 3/19 - Wednesday closed positive with 25 positive, 8 negative and 2 flats
  • 3/18 - Tuesday closed negative with 7 positive, 27 negative and 1 flat
  • 3/17 – Monday closed positive with 24 positive, 10 negative and 1 flat
  • 3/14 – Friday closed positive with 20 positive, 13 negative and 2 flats
  • 3/13 - Thursday closed negative with 4 positive, 30 negative and 1 flat
  • 3/12 – Wednesday closed positive with 25 positive, 9 negative and1 flat
  • 3/11 - Tuesday closed positive with 23 positive, 11 negative and 1 flat
  • 3/10 – Monday closed negative with 3 positive, 31 negative and 1 flat
  • 3/7 – Friday closed negative with 14 positive, 17 negative and 4 flats
  • 3/6 – Thursday closed negative with 16 positive, 18 negative and 1 flat
  • 3/5 – Wednesday closed positive with 25 positive, 9 negative and 1 flat
  • 3 /4 – Tuesday closed negative with 15 positive, 18 negative and 2 flats
  • 3/3 – Monday closed negative with 2 positive, 31 negative and 2 flats

Reiterating, “I think it's important just to take a step back, focus on the fundamentals, be selective. I mean, this has definitely been a “sucky” January and February from a stock-picker standpoint given the up/downs. And so, I am relatively neutral across today/Friday’s equity strategy.

  • Reiterating, “Take the emotion out of the sector, think of the reality of the “plays” that exist of who’s really buying.”

It’s STILL earnings season “sparking” a quarterly life crisis…

  • Cell and Gene therapy earnings continue to be important; LPS (loss per share), revenue uplifts and lags, clinical progress with some program uncertainty, a dearth all followed by estimate misses
  • The coming batch of quarterly earnings will provide last years, FY2024’s LPS (loss-per-share), some EPS, consensus meets and non-greets, cash positions, runways and partner status for investors

Earnings are STILL releasing … from Q4/24 and FY24 … with a few left; my view will follow, has been busy and personally eventful!

  •  

Think about it; one of the biggest problems with the cell and gene therapy sector’s share pricing is …  99% of them have no earnings! If rates are higher for longer, that means that sector companies will continue to struggle or be unable to raise capital and therefore be subject.

Welcome to my world of defining the “grey’ in our universe!

  • The sector is what it is, until it isn’t and even then, it doesn’t seem to be… as NOT much changes as the sector’s share pricing rides the waves of volatility, algorithms, electronic trading and short covering.
  • I am more frequently right than consequentially wrong; if I wanted to be liked, I wouldn’t have been an analyst/journalist.

 

Opinions expressed are those of the author and are subject to change, and not intended to be a forecast of future events, a guarantee of future results, nor investment advice. All investments are subject to risks. Investors should consider investment objectives.

Whether information or intelligence is good, bad or somewhere in between; I put into context what is relevant and useful for investors.  All investments are subject to risks. Investors should consider investment objectives.  Regulation Analyst Certification (Reg AC): The research analyst primarily responsible for the content of this report certifies the following under Reg AC: I hereby certify that all views expressed in this report accurately reflect my personal views about the subject company or companies and it’s or their securities. I also certify that no part of my compensation was, is or will be, directly or indirectly, related to the specific recommendations or views expressed in this report.

Henry McCusker, the editor and publisher of RegMed Investors could hold or have positions securities referred to in this publication and he will NOTIFY investors of holdings.